# Vascular Closure Devices Market

> Vascular Closure Devices Market Research Report: Size, Share, Trend Analysis By Device Type (Passive Closure Devices, Active Closure Devices, Suture Closure Devices, Collagen-based Closure Devices), By Procedure Type (Transvascular Procedures, Cardiac Procedures, Peripheral Procedures), By End Users (Hospitals, Ambulatory Surgical Centers, Specialty Clinics), By Distribution Channel (Direct Sales, Online Sales, Third-party Distributors) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 7.05%
- **2025:** USD 1.88 Billion
- **2035:** USD 3.69 Billion
- **Key Players:** Abbott, Terumo, Teleflex, Medtronic, Boston Scientific, Becton Dickinson, Cordis, Merit Medical Systems

**Report ID:** MRFR/HC/4249-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** July 03, 2026

**URL:** https://www.marketresearchfuture.com/reports/vascular-closure-devices-market-5704

---

## Market Summary

## Vascular Closure Devices Market Summary

The Vascular Closure Devices Market size was valued at USD 1.88 Billion in 2025, and the market is projected to grow from USD 2.00 Billion in 2026 to USD 3.69 Billion by 2035, registering a CAGR of 7.05% during the forecast period 2026–2035. That trajectory is anchored less to a single catalyst than to a convergence of two: the FDA's continued clearance pace for large-bore access closure platforms supporting [transcatheter aortic valve replacement](https://www.marketresearchfuture.com/reports/transcatheter-aortic-valve-replacement-market-21842) (TAVR), and CMS outpatient payment expansions that have pulled a meaningful share of elective catheterization volume into ambulatory settings. Hospitals and cath labs alike are responding by standardizing device-based closure over manual compression, particularly where access sites now routinely approach 22–25 Fr.

Below the headline number is a real technology shift. Active approximator systems and bioabsorbable collagen plugs are gradually supplanting legacy manual and figure-eight suture closure, compressing ambulation time from hours to less than sixty minutes. Industry capital flows mirror the pivot – financing rounds for closure devices and corporate R&D investments are said to have surpassed USD 400 million throughout 2023-2025, with manufacturers racing to reduce deployment time and eliminate operator-dependent variability from large-bore cases.

North America accounts for the lion’s share of the Vascular Closure Devices Market, due to its extensive cath lab infrastructure and favorable reimbursement. Asia-Pacific is the fastest-expanding region, with China and India scaling up [interventional cardiology](https://www.marketresearchfuture.com/reports/interventional-cardiology-market-8735) capacity. Europe is the second largest contributor after North America, driven by the launch of products compliant with MDR and growth in the structural heart program. As the global expansion of large-bore procedures continues, the gravity center for vascular closure, both competitive and clinical, is poised to shift from the edges of the operating room to the heart of the procedural protocol.

## Key Report Takeaways

### • By Technology

- Active approximators led the Vascular Closure Devices Market with a 50.6% revenue share in 2025, reflecting clinician preference for mechanical, suture-mediated closure in higher-volume cath labs.
- Passive approximator (collagen plug) systems are forecast to expand at a 7.5% CAGR through 2035 as bioabsorbable formulations gain traction in lower-acuity cases.
- Collagen-based materials accounted for an estimated USD 0.88 billion of the Vascular Closure Devices Market in 2025.

### • By Sector

- Interventional cardiology represented 35.2% of procedure-linked demand in 2025, the largest single procedural category.
- Neurovascular procedures are projected to post the fastest segment CAGR, at 9.9% through 2035, as endovascular stroke intervention volumes rise.
- Femoral access sites of 8 Fr or smaller held a 56.3% share in 2025, though large-bore femoral access (≥12 Fr) is the quickest-growing access category.

### • By Geography

- North America retained the largest regional position in the Vascular Closure Devices Market in 2025, supported by dense TAVR and EVAR program density.
- Asia-Pacific is forecast to grow at a 9.6% CAGR through 2035, the fastest of any region.
- Hospitals captured a 51.0% end-user share of the Vascular Closure Devices Market in 2025.

## Market Size and Forecast (2021–2035)

Figures below are based on a base-year (2025) calibration of USD 1.88 billion, projected forward at a 7.05% CAGR, and reconciled against historical procedural-volume data for 2021-2024. The Vascular Closure Devices Market will see a minor slowdown during 2021-2023 because of the postponement of elective procedures amid the pandemic, with a gradual recovery kicking in from 2024 onwards.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| TAVR/EVAR procedural volume growth | ~1.8% | Global | Long-term | [1] |
| Large-bore access device adoption (up to 25 Fr) | ~1.4% | North America, Europe | Medium-term | [2] |
| Same-day discharge/outpatient mandates | ~1.1% | North America | Short-term | [3] |
| Bioabsorbable closure material innovation | ~0.9% | Global | Medium-term | [4] |
| Aging population & rising PAD prevalence | ~1.0% | Asia-Pacific, Europe | Long-term | [5] |
| Reimbursement expansion for ambulatory procedures | ~0.7% | North America | Short-term | [6] |
| Femoral access procedural standardization | ~0.5% | Global | Medium-term | [7] |

### TAVR and EVAR Procedural Growth

Transcatheter aortic valve replacement volumes in the United States alone have climbed past an estimated 150,000 annual procedures, and each case routinely requires large-bore closure. As CMS coverage criteria broaden into lower-risk patient cohorts, closure-device pull-through scales proportionally with procedural count rather than with hospital count, concentrating demand growth in high-volume centers [[1]](https://scai.org).

### Large-Bore Access Standardization

Device clearances supporting access sites up to 25 Fr have expanded materially since 2022, and several large academic centers now report device-based closure rates above 85% for structural heart cases — up from roughly 60% five years prior [[2]](https://fda.gov).

### Outpatient and Same-Day Discharge Mandates

CMS removal of select [cardiac catheterization](https://www.marketresearchfuture.com/reports/cardiac-catheterization-market-972) procedures from the inpatient-only list has pushed same-day discharge protocols into mainstream use, and predictable hemostasis is a prerequisite for early ambulation pathways that hospitals depend on to manage bed capacity [[3]](https://cms.gov).

## Restraints

## Restraints Impact Analysis

As with drivers, restraint impact figures are directional approximations of downward pressure on CAGR and are not strictly additive.

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| High device cost vs. manual compression | ~1.2% | Emerging markets | Short-term | [8] |
| Vascular complication risk (pseudoaneurysm, infection) | ~0.8% | Global | Medium-term | [9] |
| Reimbursement variability across geographies | ~0.6% | Asia-Pacific, Latin America | Medium-term | [10] |
| Operator training and learning curve | ~0.5% | Global | Short-term | [11] |
| Stringent regulatory pathways for new materials | ~0.4% | Europe (MDR) | Long-term | [12] |

### Cost Sensitivity in Price-Constrained Systems

A single active approximator device can carry a per-unit cost several multiples above manual compression supplies, a gap that public hospital systems in price-sensitive markets are slow to absorb without bundled procedural reimbursement [[8]](https://worldbank.org).

### Regulatory Friction Under EU MDR

Post-MDR conformity reassessment has lengthened average time-to-market for new collagen and polymer-based closure formulations in the EU by an estimated 9–14 months relative to the prior medical device directive regime, slowing the pace of next-generation product launches in the region [[12]](https://ec.europa.eu).

## Opportunities

## Vascular Closure Devices Market Opportunities

### Fully Resorbable Closure Platforms

Manufacturers investing in fully bioabsorbable plug and approximator chemistries stand to capture share from clinicians wary of permanent intravascular hardware, particularly in younger structural heart patients who may require repeat access.

### Large-Bore Systems Tied to Structural Heart Expansion

As TAVR indications broaden, closure platforms purpose-built for 22–25 Fr sheaths represent a high-margin, high-growth adjacency tightly coupled to structural heart program build-out.

### Emerging Market Cath Lab Build-Out

India and Southeast Asia are adding catheterization lab capacity faster than device-based closure penetration is rising, leaving a meaningful conversion opportunity as manual compression remains the default in many tier-2 hospitals.

### Procedural Data and Outcomes Registries

Device makers bundling closure hardware with cloud-based outcomes tracking and registry participation are opening new service-revenue lines beyond the device sale itself, mirroring data-monetization models seen elsewhere in interventional cardiology.

### Radial-Specific Compression Innovation

As operators migrate select procedures from femoral to radial access, compression-band design tailored to radial hemostasis addresses a procedural segment that traditional femoral closure platforms do not serve.

## Future Outlook

## Vascular Closure Devices Market Future Outlook

### AI-Assisted Procedural Planning

Predictive software that recommends closure device type based on access-site anatomy and patient risk profile is moving from pilot programs into commercial rollout, with early adopters reporting fewer access-site complications.

### Platform Economics

Manufacturers are increasingly bundling closure devices across multiple access sizes into single procedural kits, shifting competitive emphasis from individual device performance toward portfolio breadth and hospital system contracting.

### Outpatient and Ambulatory Economics

As same-day discharge protocols mature, hospital procurement decisions are weighing closure-device reliability and ambulation-time predictability more heavily than unit price, reshaping vendor selection criteria.

### ESG and Supply Chain Reporting

Device manufacturers are beginning to disclose sterilization energy use and packaging waste metrics in response to investor and hospital-system ESG procurement criteria, a trend expected to influence vendor scorecards through the back half of the forecast period.

## Segment Insights

## Vascular Closure Devices Market Segmentation

### By Product Type

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Active Approximators | 50.6% share (2025) | Mechanical suture-mediated closure preference |
| Passive Approximators | 7.5% CAGR (2026–2035) | Bioabsorbable collagen plug adoption |

Active approximators remain the clinical default in high-volume cath labs because of consistent deployment time, while passive approximator systems are gaining ground as collagen-based formulations improve reabsorption profiles.

### By Material Composition and Mode of Access

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Collagen-Based | USD 0.88 Billion (2025) | Established clinical track record |
| Suture/Filament-Based | 9.3% CAGR (2026–2035) | Reusability across repeat-access patients |
| Femoral Access ≤8 Fr | 56.3% share (2025) | Standard diagnostic and low-acuity procedures |
| Large-Bore Femoral ≥12 Fr | 7.1% CAGR (2026–2035) | TAVR/EVAR case volume growth |

Collagen-based systems retain the largest material share given decades of clinical familiarity. However, suture and filament-based platforms are growing fastest as operators value their compatibility with repeat femoral access.

### By Procedure Type

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Interventional Cardiology | 35.2% share (2025) | High procedural volume base |
| Neurovascular | 9.9% CAGR (2026–2035) | Endovascular stroke intervention growth |
| Peripheral Vascular | USD 0.34 Billion (2025) | PAD prevalence increases |
| Structural Heart/TAVR | 8.4% CAGR (2026–2035) | Large-bore indication expansion |

Interventional cardiology remains the anchor procedural category, but neurovascular procedures are scaling fastest as stroke-center networks expand mechanical thrombectomy capacity.

### By End User

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Hospitals | 51.0% share (2025) | Comprehensive procedural capability |
| Catheterization Labs / ASCs | 7.8% CAGR (2026–2035) | Shift toward ambulatory procedural settings |
| Outpatient Vascular Centers | USD 0.21 Billion (2025) | Same-day discharge protocol adoption |

Hospitals continue to handle the bulk of complex large-bore cases. Still, standalone catheterization labs and ambulatory surgical centers are absorbing a growing share of lower-acuity diagnostic and peripheral procedures.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 37.4% market share | Large-bore platforms, outpatient cath labs |
| Europe | USD 0.51 Billion | MDR-compliant launches, structural heart growth |
| Asia-Pacific | 9.6% CAGR (2026–2035) | Cath lab infrastructure build-out, China/India volume growth |
| South America | 6.0% market share | Private hospital network expansion |
| Middle East & Africa | USD 0.11 Billion | Tertiary cardiac center investment |
| **Total** | **USD 1.88 Billion (2025)** | — |

### North America

| Country | Key Metric (Share of Region) | Key Driver |
| --- | --- | --- |
| US | 84% | TAVR/EVAR program density |
| Canada | 10% | Provincial reimbursement expansion |
| Mexico | 6% | Private hospital cath lab growth |

North America's lead rests on procedural depth rather than procedural count alone: high-volume academic centers concentrate large-bore case mix and have effectively normalized device-based closure as standard of care, a pattern reinforced by CMS site-of-service payment changes.

### Europe

| Country | Key Metric (Share of Region) | Key Driver |
| --- | --- | --- |
| Germany | 24% | High TAVR center density |
| UK | 18% | NHS elective recovery programs |
| France | 14% | Structural heart reimbursement reform |
| Italy | 11% | Cath lab modernization |
| Spain | 9% | Public hospital procurement cycles |
| Nordic Countries | 8% | Early bioabsorbable adoption |
| Russia | 7% | Tertiary center expansion |
| Rest of Europe | 9% | Gradual device-based closure conversion |

Germany's scale advantage stems from its dense network of TAVR-capable centers, while UK volumes are recovering unevenly as NHS trusts work through elective procedure backlogs accumulated over prior years.

### Asia-Pacific

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| China | 32% share of region | Domestic device manufacturing scale-up |
| India | 11.2% CAGR (2026–2035) | Cath lab capacity expansion |
| Japan | 22% share of region | Aging population, PMDA approval pace |
| South Korea | 12% share of region | Reimbursement parity with Western devices |
| ASEAN | 9% share of region | Private hospital network growth |
| Rest of Asia-Pacific | 8% share of region | Early-stage interventional cardiology buildout |

China's domestic manufacturers are narrowing the technology gap with multinational players. At the same time, India's growth is driven primarily by new cath lab installations outpacing the current rate of device-based closure adoption.

### South America

| Country | Key Metric (Share of Region) | Key Driver |
| --- | --- | --- |
| Brazil | 58% | Private hospital network scale |
| Argentina | 24% | Reimbursement policy reform |
| Rest of South America | 18% | Gradual cath lab modernization |

Brazil's private hospital networks have led regional adoption, with public-sector uptake lagging due to procurement cycle constraints.

### Middle East & Africa

| Country | Key Metric (Share of Region) | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 27% | Vision 2030 healthcare infrastructure investment |
| UAE | 23% | Medical tourism-linked tertiary centers |
| South Africa | 19% | Private hospital group expansion |
| Egypt | 14% | Cath lab capacity growth |
| Rest of MEA | 17% | Early-stage market development |

Saudi Arabia's growth is closely tied to national healthcare infrastructure investment programs that are funding new tertiary cardiac centers across the kingdom.

## Competitive Benchmarking

## Competitive Benchmarking

The Vascular Closure Devices Market is moderately concentrated, with the top-5 companies projected to hold a combined revenue share in the region of 55-65% and an approximate HHI in the moderately concentrated band. No vendor is a clear leader, and competitive differentiation is driven by speed of deployment, big bore compatibility and bioabsorbable material innovation.

| Company | Est. Revenue Share Range | Key Offerings for the Vascular Closure Devices Market | Strategic Positioning |
| --- | --- | --- | --- |
| Abbott | ~14–17% | Active approximator and suture-mediated closure systems | Broad cath lab portfolio integration |
| Terumo | ~11–14% | Collagen-based and radial compression devices | Strength in Asia-Pacific distribution |
| Teleflex | ~10–13% | Collagen plug and large-bore closure platforms | Acquisitive growth via niche device makers |
| Medtronic | ~9–12% | Vascular closure adjacent to the structural heart portfolio | Bundled TAVR procedural kits |
| Boston Scientific | ~8–11% | Peripheral and femoral access closure devices | Peripheral vascular franchise leverage |
| Becton Dickinson | ~6–9% | Suture-based and access-site management devices | Hospital procurement scale |
| Cordis | ~5–8% | Femoral closure systems | Legacy interventional cardiology base |
| Merit Medical Systems | ~4–7% | Compression and closure accessory devices | Cost-competitive positioning |
| Haemonetics (Cardiva) | ~3–6% | Mechanical, non-implant closure devices | Differentiated reversible-mechanism platform |
| InSeal Medical | ~2–4% | Large-bore vascular closure systems | Structural heart-focused niche entrant |

## Recent News & Developments

## Recent News & Developments

- Terumo (January 2024): Announced a distribution partnership to expand radial compression band availability across Southeast Asia [[15]](https://terumo.com).

- Boston Scientific (November 2023): Disclosed peripheral vascular portfolio investment, including closure-adjacent access management tools [[17]](https://bostonscientific.com).

- EU MDR Notified Bodies (2024): Issued updated guidance affecting conformity reassessment timelines for collagen-based implantable closure materials [[12]](https://ec.europa.eu).
- CMS (2023): Finalized outpatient payment rule changes affecting site-of-service economics for select catheterization procedures [[3]](https://cms.gov).

## Report Scope

## Vascular Closure Devices Market Report Scope

| Parameter | Detail |
| --- | --- |
| Market Scope | Vascular closure devices across product type, material composition, access mode, procedure, end user, and geography |
| Study Period | 2021–2035 |
| CAGR | 7.05% (2026–2035) |
| Market Size Checkpoints | 2025: USD 1.88 B; 2026: USD 2.00 B; 2031: USD 2.81 B; 2035: USD 3.69 B |
| Fastest Growing Segments | Neurovascular procedures; Asia-Pacific region; large-bore femoral access |
| Companies Profiled | 10 (Section 10) |
| Valuation Currency | USD Billion |

## Frequently Asked Questions

**Q: What should hospital procurement teams weigh most when comparing closure-device vendors?**
A: Deployment consistency across operators matters more than unit price alone. Vendors with documented complication-rate data across diverse access sizes typically win multi-year contracts [9].

**Q: How do bioabsorbable and permanent-implant closure devices differ in practice?**
A: Bioabsorbable devices dissolve over weeks, reducing concerns about repeat-access interference. Permanent implants offer faster deployment but carry long-term foreign-material considerations [4].

**Q: Is device-based closure replacing manual compression entirely?**
A: No. Manual compression remains common for low-acuity diagnostic cases, especially in cost-constrained settings. Device-based closure concentrates in large-bore and high-volume procedural environments [8].

**Q: What regulatory nuance affects new closure-material launches in Europe?**
A: EU MDR conformity reassessment has extended approval timelines for implantable materials. Manufacturers now budget longer commercialization windows for collagen and polymer-based products [12].

**Q: Are there integration challenges when adopting AI-assisted closure-selection tools?**
A: Yes — integration with existing electronic health record and cath lab imaging systems remains uneven. Hospitals piloting these tools report workflow friction during the first implementation phase.

**Q: How does radial access growth affect closure-device demand?**
A: Radial procedures use compression bands rather than implantable closure devices, so volume migration toward radial access shifts revenue toward a different product category entirely [7].

**Q: What competitive dynamic is reshaping smaller closure-device manufacturers?**
A: Niche players like InSeal Medical are being acquired or partnered with by larger vendors seeking large-bore portfolio gaps, consolidating innovation under established distribution networks [18].

**Q: What is the current size of the vascular closure devices market?**
A: The vascular closure devices market reached USD 1.88 billion in 2025 and is projected to reach USD 3.69 billion by 2035.

**Q: What is the CAGR of the vascular closure devices market?**
A: The vascular closure devices market is projected to grow at a CAGR of 7.05% during the forecast period 2026–2035.

**Q: Which region leads the vascular closure devices market?**
A: North America holds the largest share at 37.4%, while Asia-Pacific is the fastest-growing region at 9.6% CAGR.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/vascular-closure-devices-market-5704*